GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Health&Life Co 1781.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

8.30

-2.35%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Health&Life Co

Its shares trade on Taipei Exchange under the ticker 1781.TWO. It has been listed since 9 January 2004. In the fiscal year to 31 December 2025, it reported revenue of TWD 398.0m and a net loss of TWD 61.7m. At that date it held total assets of TWD 723.1m and shareholders' equity of TWD 320.6m.

Health & Life Co., Ltd. engages in the manufacture and distribution of cardiovascular disease, in-vitro diagnostics and respiratory care products. The company is headquartered in Taipei, New Taipei. The company went IPO on 2004-01-09. The firm's mainly provides electronic sphygmomanometers, such as blood pressure monitors, nebulizers and blood glucose monitoring systems, which are used to measure and record systolic and diastolic blood pressure and glucose of human beings. The firm distributes its products within domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
9 Jan 2004
Employees
400

Leadership

Pay as last reported

  • Mr. Guohe YangChairman of the Board, Chief Executive Officer, since 1999
  • Shaohong LiGeneral Manager
  • Xunlu XuDeputy General Manager-Finance & Management
  • Shufen LiHead of Finance & Accounting, Corporate Governance Officer
  • Yufeng HongDirector
  • Shuzhen LianDirector
  • Hengjiang HuangIndependent Director
  • Fangrong LuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Health&Life Co Ltd manufactures electronic sphygmomanometers for cardiovascular health monitoring in Taiwan.
  • The company's domestic market presence supports stable revenue streams within Taiwan.
  • Health&Life Co Ltd's product range includes blood glucose monitoring systems for diabetes management.

Weaknesses

  • The company's reliance on the domestic market limits international expansion opportunities.
  • Health&Life Co Ltd has only 400 employees, which may constrain operational capacity.
  • The firm's focus on cardiovascular and respiratory care products restricts diversification.

Opportunities

  • Growing demand for home healthcare devices in Taiwan presents new market potential.
  • Expanding into overseas markets could increase revenue from international sales.
  • Increasing prevalence of diabetes in Asia drives demand for blood glucose monitoring systems.

Threats

  • Competition from global health tech firms may impact market share in Taiwan.
  • Regulatory changes in the Health Care sector could affect product approvals.
  • Economic downturns might reduce consumer spending on healthcare devices.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.